Physician profile
Michael S Mccracken
NPI 1043291701
$3,869.40
in general payments reported to CMS, 2019-2025
8 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 78% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $401 · 2021: $493 · 2022: $210 · 2023: $754 · 2024: $361 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,148.60 | 2023-2025 | |
| Allergan, INC. | $1,125.71 | 2019-2022 | |
| Galderma Laboratories, L.P. | $615.96 | 2019-2025 | Dysport |
| Merz North America, INC. | $342.80 | 2023-2024 | Xeomin |
| Stryker Corporation | $325.06 | 2023-2025 | Medpor Titan, Sonopet Iq |
| Horizon Therapeutics Plc | $157.92 | 2020 | |
| Revance Therapeutics, INC. | $121.34 | 2025 | Daxxify |
| Glaukos Corporation | $32.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccracken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.